Cabaletta Bio Reports $43.5 Million Net Loss in Q1 2026, Increases R&D Spending

Cabaletta Bio, Inc. reported a net loss of $43.5 million for the first quarter of 2026, an increase from a loss of $35.9 million during the same period in 2025. The company's total operating expenses rose to $44.3 million, up from $37.1 million year-over-year, primarily driven by increased research and development costs, which reached $37.4 million compared to $29.0 million in the prior year. The increase in R&D expenses was attributed to higher clinical trial costs and expanded manufacturing capabilities, reflecting the company's ongoing commitment to advancing its lead product candidate, rese-cel, through clinical trials.

Cabaletta's cash and cash equivalents stood at $116.6 million as of March 31, 2026, a decrease from $138.9 million at the end of 2025. The company raised approximately $141 million in May 2026 through a public offering of common stock, which is expected to fund operations into mid-2027. Despite this capital influx, the company has expressed substantial doubt about its ability to continue as a going concern, citing the need for additional funding to support ongoing research and development activities.

In terms of operational developments, Cabaletta has made significant strides in its clinical programs. The company is currently conducting multiple Phase 1/2 clinical trials for rese-cel, targeting various autoimmune diseases, including systemic lupus erythematosus and dermatomyositis. The FDA has granted Fast Track and Orphan Drug designations for rese-cel, which may expedite its development and regulatory review process. Additionally, the company has entered into a commercial supply agreement with Cellares Corporation for the automated manufacturing of rese-cel, enhancing its production capabilities.

Cabaletta's workforce has expanded, with an increase in personnel costs reflecting the hiring of additional staff to support its growing clinical programs. The company is also reliant on key partnerships for manufacturing and development, including agreements with Minaris Advanced Therapies and Lonza Houston, which are critical for the production of its product candidates. The company’s future success hinges on its ability to navigate the complexities of clinical development, secure regulatory approvals, and ultimately commercialize its therapies.

Looking ahead, Cabaletta anticipates continued increases in both research and development and general administrative expenses as it progresses through its clinical trials and prepares for potential commercialization. The company remains focused on securing additional funding through equity offerings and collaborations to sustain its operations and advance its product pipeline.